
The IAMPOCO trial enrolls 40 PCS patients in a crossover, sham-controlled design to assess the impact of antibody removal on symptom severity. Participants receive five immunoadsorption and five sham treatments. Primary outcomes include symptom score changes and hand grip strength. Findings may offer evidence-based therapeutic options for PCS and improve treatment strategies for affected individuals.
Like
Save
Share